Introduction
It has been more than 50 years since Charles Huggins identified the utility of castration therapy for advanced prostate cancer (Huggins and Hodges, 1941) . Since then, the means of castration therapy have changed significantly but the ultimate goal of the therapy for the prostate cancer patient remains the same; the blockade of androgenic steroid action. This therapy is rarely, if ever, curative. For most patients, it provides rapid symptomatic relief as well as a temporary respite from tumor advancement leading to a slight, but significant increase in survival (Resnick and Grayhack, 1975; Murphy and Slack, 1980) . Unfortunately for these patients, a subpopulation of the cancer cells are resistant to hormonal therapy, and it is these hormoneresistant cancer cells that are responsible for the predictable recurrence experienced by advanced prostate cancer patients following hormonal treatment. Moreover, once a prostate tumor has acquired resistance to hormone therapy, it often demonstrates cross-resistance to non-hormonal based therapies such as radiation or chemotherapy. For these reasons, hormone-resistant prostate cancer is an ideal target for the design and development of more effective prostate cancer therapeutics.
Given this background, one of the more important goals of research on prostate cancer is the identification of the molecular basis for therapeutic resistance by prostate cancer cells. In the past, it was thought that resistance (at least to hormonal agents) would be generally attributed to defects/deficiencies in the androgen receptor protein (AR) of the prostate cancer cell. AR mutations and deficiencies have been detected in some human prostate cancers, but these defects are found at too low a frequency to account for the abundant generation of therapeutic resistance observed in prostate cancer patients (van der Kwast et al., 1991; Taplin et al., 1995 Taplin et al., , 1999 Marcelli et al., 2000) . Recent studies also suggest that androgen receptor transcriptional activity can be activated or amplified under conditions of low androgen through several growth factor or cytokine-stimulated signaling pathways (Yeh et al., 1999; Craft et al., 1999; Grossman et al., 2001) or by interaction with specific AR-binding co-factors (Hsiao and Chang, 1999; Whang et al., 2001) . Finally, advances in our understanding of the relationship between androgenwithdrawal and the onset of apoptosis of prostate cancer cells have also led to intense study as to whether gene products that mediate the apoptotic process might also be involved in the generation of therapeutic resistance of prostate cancer. As a result of these studies, we now know that the bcl-2 protein, a potent inhibitor of apoptosis, is frequently overexpressed in hormone resistant human prostate cancers (Raffo et al., 1995; Krajewski et al., 1996; McDonnell et al., 1997) . Institutional surveys of hormone-resistant human prostate cancers for bcl-2 overexpression have found differing prevalence of this biomarker, ranging from 35 to over 60% of such specimens analysed Furuya et al., 1996; McDonnell et al., 1997) . Again, these numbers fail to account for all cases of hormone resistant prostate cancer and it is imperative that the search for the genetic basis of hormone (and other therapeutic) resistance in prostate cancers be continued.
Obviously, given the large number of factors that have already been shown to influence the response of the prostate cancer cell to androgens, the development of natural therapeutic resistance to androgen withdrawal by prostate cancer cells is likely to involve diverse and complex molecular mechanisms, only a few of which are presently understood. In an attempt to develop a model system that might enable us to learn more about the genetic basis for therapeutic resistance of prostate cancer cells, we describe here experiments leading to the production of two independent apoptosis-resistant prostate cancer cell lines in vitro. These lines were developed by repeated serial exposure of a parental prostate cancer cell line, LNCaP, to agents (phorbol ester and serum starvation) that induce apoptosis of the majority of cells in the parental culture (Raffo et al., 1995) . By repeatedly expanding the populations that were able to survive a limited exposure to these conditions, we ultimately obtained cell lines with a generic 'apoptosis-resistant' phenotype. Then we applied a subtractive hybridization-PCR technology to comparatively analyse the apoptosis resistant cell lines and to characterize unique gene products that are differentially expressed in these lines. Through this procedure, we identified a novel gene product, protocadherin-PC, that does distinguish the apoptosisresistant variants from the parental LNCaP line. Analysis of the apoptotic sensitivity of parental cells transfected with protocadherin-PC cDNA supports the ability of this unusual molecule to confer the apoptotic resistance phenotype.
Results

Derivation of apoptosis-resistant LNCaP cell variants
LNCaP is an androgen-responsive human prostate cancer-derived epithelial cell line frequently utilized for prostate cancer research. These cells can be induced to undergo apoptosis in vitro by exposure to phorbol esters (TPA at 10 nM) or to conditions of serum starvation (Raffo et al., 1995) . In an attempt to create naturally apoptosis-resistant LNCaP cell lines, we repeatedly exposed cultured parental LNCaP cells to brief periods (24 h) of medium containing 10 nM TPA (phorbol ester) or to a medium lacking serum (serumstarvation) (Figure 1a ). These conditions were previously shown to be sufficient to induce apoptosis of 80 -85% of the cells in culture. The cell populations that survived this initial exposure were then expanded in normal medium until the cultures reached 80% confluence, at which time they were again exposed to the selective medium (containing TPA or lacking serum) for another 24 h. This process was repeated five times (see Figure 1a) and resulted in the derivation of two independent cell lines that we termed LNCaP-TR (for TPA-resistant) and LNCaP-SSR (for serum starvation resistant) that were found to be highly resistant to the agent used in the generation of the line (TPA for LNCaP-TR and serum starvation for LNCaP-SSR) (Figure 1b ). When these cell lines were tested against the agent that was not utilized in their selection (serum starvation for LNCaP-TR and TPA for LNCaP-SSR) they were found to demonstrate cross-resistance to the unexposed agent (Figure 1b) . Moreover, these cells were found to have a hormoneresistant phenotype when tested for their ability to form tumor xenografts in castrated male nude mice. In contrast to the parental LNCaP cells which were not able to form tumors when xenografted subcutaneously into castrated male nude mice (n=10), seven out 10 castrated mice xenografted with the LNCaP-TR cells and nine of 10 castrated mice xenografted with LNCaP-SSR cells formed large tumors within 6 weeks of the implantation (P50.005). Thus we consider these cell lines to be generically resistant to apoptosis, especially when compared to the parental line (LNCaP) from which they were derived. With regards to other characteristics of the derivative cell lines, there were no noticeable morphological differences between the parental LNCaP and either of the two sublines. Nor were their any evident differences in growth rates noted during standard passage of the sublines compared to the parental line. Preliminary characterization of the expression of some common apoptosis-regulatory molecules in the -TR and -SSR cell lines by comparative Western blot analysis and densitometry showed that the levels of AR protein, prostate specific antigen, p53 and HER-2/neu protein were not significantly different from the parental LNCaP cells whereas the expression of bclX L and bcl-2 protein appeared to be 2 -4-fold elevated in the -SSR and -TR cells, respectively ( Figure 1C ).
Subtractive hybridization to identify unique gene products expressed in LNCaP-TR Cells
We compared potential genetic differences between the parental LNCaP cells and the -TR variant line using a subtractive hybridization-PCR procedure (Diatchenko et al., 1996) . The resulting -TR-specific cDNA fragments that were recovered from this subtractive hybridization-PCR technique were cloned into a plasmid vector and these plasmids were purified and sequenced. Of 21 cDNA inserts analysed, only three unique sequence cDNA fragments were identified from this procedure, two that matched sequences already in genbank (not discussed here) and were representative of gene products that are inducible by phorbol ester stimulation, whereas one unique cDNA fragment (249 bp), designated T6, was found not to have significant homology to other sequences that were currently in genbank.
The 249-bp T6 tag sequence was radiolabeled and used as a probe for Northern blots containing RNAs extracted from parental LNCaP and the derivative cell lines (Figure 2a) . Hybridization of the Northern blot with the T6 tag probe identified a prominent 4.8 kb mRNA that was found to be abundantly expressed in the LNCaP-TR and -SSR lines but not in the parental LNCaP cells. Less abundant transcripts with homology to the T6 tag of 4.0 and 3.1 kb were also expressed by the apoptosis-resistant cells. When parental LNCaP cells were chronically cultured in a medium depleted of androgens and other hormones (by use of charcoal-stripped serum), they also acquired abundant expression of the T6-homologous mRNAs (Figure 2a) . Likewise, LNCaP cells grown as subcutaneous xenograft tumors in male nude mice were found to acquire expression of T6-homologous RNAs following chronic castration of the host. At 4 weeks subsequent to castration, a time when the xenografts begin to regrow as an androgenindependent tumor (Raffo et al., 1995) , RNase protection assay showed abundant expression of T6-related transcripts in contrast to the low abundance of this transcript in xenografts growing in androgenically normal mice or at 2 days after castration (Figure 2b ).
The gene product of T6, a new protocadherin-family member
Sequence information from the T6 tag fragment was used to generate PCR primer sets for 5' and 3' RACE procedures to obtain the complete sequence of the homologous 4.8 kb cDNA. These procedures resulted in the cloning of complete 5' and 3' cDNA fragments, each of which were sequenced by C Figure 1 (a) Schematic derivation of apoptosis-resistant LNCaP variants. Parental LNCaP cells were transiently exposed (24 h) to apoptosis-inducing medium (deprived of serum or containing 10 nM phorbol ester [TPA] ). Surviving cells were transferred and expanded in normal medium and were subject to a second round of the same selection just prior to confluence. Selection was repeated for a total of five times to yield the final variants, LNCaP-TR (TPA-resistant) or LNCaP-SSR (serum starvation resistant) that were used in the identification of the T6 gene product. (b) Results of MTT assay demonstrating cell viability of LNCaP variants, as indicated, after exposure to 24 h of serum starvation or to TPA. Cell survival is determined by MTT assay and is compared to the results when the same cells were grown in normal (10% FBS-containing) medium. Results were analysed by a student t-test comparing the results of LNCaP-SSR or LNCaP-TR to the parental LNCaP. The response of these cells to apoptotic agents were significantly attenuated when compared to the parental line (*P50.05). (c) Western blot analysis of protein extracts from LNCaP cell variants show comparative expression of AR, PSA, p53, bcl-2, bcl-XL or erb-B2 protein standard dideoxynucleotide techniques. Analysis of the complete sequence for the 4.8 kb cDNA ( Figure  3a) showed the presence of two potential overlapping long open reading frames. Utilization of the first potential AUG at position 614 would yield a peptide of 1037 amino acids (M.W. 114 784) that contains a signal sequence at its N-terminus whereas utilization of the second potential AUG (at position 857) would yield a peptide of 956 amino acids that lacks a signal sequence (Figure 3a ). Both translation products would have the same seven sequential regions that are characteristic of cadherin box domain sequences near the N-terminus. This cDNA thus identifies a potential member of the cadherin superfamily of gene products and we have named it protocadherin-PC based upon the multiple nature of the cadherin box domains (more than five) that would be present in its protein products (a characteristic of the cadherin subfamily referred to as protocadherins) (Suzuki, 1996) and because computerized (Fasta) searches of Genpept hit several protocadherins with E less than 0.001, but not classical cadherins with that low an E value. Indeed, this transcript has complete homology with a potential product of a gene (PCDHY) previously reported to reside on the human Y-chromosome (at Yp11.2) (Blanco et al., 2000) . In addition, it shares extensive (but not complete) homology with another gene (PCDHX) present on the human X-chromosome (at Xq21.3) (Yoshida and Sugano, 1999) from which it was proposed to originate by a duplication occurring during the evolution of humans from other primates. Thus, protocadherin-PC appears to be a human-restricted gene product. To further confirm that the apoptosis-resistant LNCaP variants were specifically upregulating expression of the Ychromosome encoded gene product, we performed an RT -PCR amplification of LNCaP-cell variant mRNAs using a primer set that would enable distinction of the X-chromosome homolog from the Y-chromosome homolog. This primer set amplifies a specific region of these two gene products that share complete homology with the exception of a 13-bp region that is deleted from the sequence of the Yencoded gene product. Our results (Figure 3b) show that the smaller amplification product (555 bp) characteristic of the Y-chromosomal gene product is comparatively over-expressed in the apoptoticresistant variants of LNCaP and confirm that the Yencoded homolog of this highly related pair of genes is the transcript that is upregulated in the apoptosisresistant cells.
Expression of protocadherin-PC cDNA in transfected LNCaP cells confers an apoptosis-resistant phenotype
The protocadherin-PC cDNA was cloned into the PC-3-neo mammalian expression vector and was used to stably transfect parental LNCaP cells. Transformed cells were selected by exposure to G418 and several clonal isolates were derived. The clonal isolates were expanded and individual clones were extracted for RNA. The RNA was analysed for expression of the protocadherin-PC mRNA by a comparative RT -PCR procedure in which protocadherin-PC expression is compared to a housekeeping gene, TBP (Figure 4a ). Three of these clonal isolates were selected for further analysis based on the variation in expression levels of protocadherin-PC (T6-5 [very low expression]; T6-4 [moderate expression]; and T6-2 [high expression]). These three clones were tested for their ability to survive a 24-h exposure to various doses of TPA and were compared to the survival properties of the apoptosis-resistant LNCaP-TR cells or the parental (apoptosis-sensitive) LNCaP cells using an MTT assay. As is shown in Figure 4b , the -TR variant as well as the high-expressing T6-2 line were much better able to survive an acute exposure to phorbolester induced apoptosis when compared to the apoptosis-sensitive parental cells (P50.001). The RNase protection assay for T6-related mRNA expression in RNA extracted from individual LNCaP xenograft grown in an adult male mouse (intact) or from a host mouse at 2 days or 4 weeks after castration. Control lane (Yeast tRNA) was riboprobe hybridized to yeast tRNA prior to nuclease digestion. Intact riboprobe was undigested with Rnase. Results identify upregulation of the t6-homologous mRNA during progression of the xenograft to the androgen-independent state moderately-expressing T6-4 line was also less sensitive to TPA than the parental line (P=0.012) whereas the low/non-expressing transformant, T6-5 was as sensitive to phorbol ester as the parental cell line (P=0.707). These results support the concept that expression of protocadherin-PC is associated with the acquisition of apoptosis-resistance (at least to phorbol esters) in a dose-dependent manner. A 15-amino acid peptide corresponding to residues 829 -843 of the predicted protocadherin-PC polypeptide was synthesized and used to repeatedly immunize rabbits. Serum from immunized rabbits was used to probe a Western blot that contained proteins extracted from parental LNCaP cells and from the -TR and -SR variants. This serum specifically recognized a protein of approximately 110-kDa on Western blots that was present in abundance in the apoptosis-resistant LNCaP variants but was only present in trace amounts in the parental LNCaP cells (Figure 5a) . A similar sized protein recognized by the antiserum was found to be abundantly present in extracts made from LNCaP tumor xenografts obtained after castration of the host mouse, but not before (Figure 5a ). Cellular fractionation showed that this 110-kDa antigen was cytoplasmically localized (Figure 5b ) and together, these observations support the likely identify of the 110-kDa band on Western blots as the second potential translation product (lacking a signal sequence) encoded by the protocadherin-PC transcript.
The protocadherin-PC translation products also contain a serine-rich region near the C-terminal with partial homology to the b-catenin-binding site found on several classical cadherins (Figure 6a ) (Stappert and Kemler, 1994) . In order to confirm the potential for bcatenin binding by the protocadherin-PC protein, we directly immunoprecipitated protocadherin-PC from cytosolic extracts of the LNCaP cell variants and then tested these immunoprecipitates by means of Western blotting to determine whether b-catenin protein was co-precipitated. The results of the Western blot ( Figure  6b) showed that the 94-kDa b-catenin protein was present in the immunoprecipitates of the -TR and -SSR cells but not from the parental LNCaP cell that express low levels of protocadherin-PC mRNA.
Discussion
The goal of the experiments described here was to identify and characterize potentially novel genetic means by which prostate cancer cells can acquire the ability to escape hormonal as well as other forms of therapy. While most current studies of therapeutic resistance of prostate cancer focus on the aberrant activity of AR in the presence or absence of androgens or on expression of the bcl-2 oncoprotein, we have now been able to describe a very unusual member of the protocadherin gene family, protocadherin-PC, and have obtained preliminary evidence that this gene product is also potentially involved in generating apoptosis resistance (and therapeutic resistance) of one type of prostate cancer cell (the LNCaP line). In our preliminary observations, we have shown that mRNA encoding protocadherin-PC is significantly elevated in LNCaP cell derivatives (-TR and -SSR) that demonstrate a generic resistance to apoptotic signals. These cells were selected from a parental cell line (LNCaP) that has the ability to upregulate protocadherin-PC expression when chronically exposed to hormone-depleted conditions (in culture or in tumor xenografts). These data identify a strong correlative relationship between the upregulation of protocadherin-PC expression and the acquisition of therapeutic resistance by prostate cancer cells, in vivo and in vitro. It should also be noted that the apoptosis-resistant derivatives appear to express higher levels of bcl-2 and bcl-X L protein than the parental cells as assessed by Western blot analysis. Certainly, it is possible that the apoptosis-resistant phenotype of the derivative cell lines is a simple function of the elevated expression of these two apoptosis-suppressing gene products. However, our transfection studies using protocadherin-PC support the idea that simple over-expression of protocadherin-PC leads to an apoptosis resistant phenotype. It is possible that elevated protocadherin-PC expression somehow induces expression of bcl-2 and bclX L and we will be examining for any potential relationship between protocadherin-PC expression and expression of other anti-apoptotic molecules in future work.
The two homologous potential translation products of the protocadherin-PC transcript are distinct members of the protocadherin gene family. In literature, protocadherin gene products are generally found to be expressed in brain and other nervous tissue of mammalian organisms and it has been proposed that protocadherins are involved in neuronal tissue development (Suzuki, 1996) . Although the actual function of any protocadherin gene family member remains uncharacterized, it is presumed that they have a role in cellular adhesion similar to the classical cadherins. Indeed, most protocadherins, likewise the classical cadherins that are more well characterized, are usually found to be membrane associated. The protocadherin-PC transcript we describe here clearly has the potential to encode a protein with a distinct signal sequence and transmembrane domain, however, it has an even greater potential of producing a translation product that lacks a signal sequence from a second AUG start site further downstream of the first based upon the stronger Kozak concensus sequence adjacent to the more internal AUG (Yoshida and Sugano, 1999) . Our demonstration that an antibody raised against a common peptide recognizes a cytoplasmically-localized protein only supports the idea that the shorter translation product lacking the signal sequence is the primary translation product from this transcript. Moreover, we have recently produced a myc-tagged protocadherin-PC cDNA that induces a strong cytoplasmic immunostaining using the anti-myc tag antibody (not shown here) and this further confirms our sense that protocadherin-PC preferentially produces a non-membrane bound translation product which is unusual for the protocadherin gene family. Moreover, this finding suggests that protocadherin-PC is not influencing the apoptosis sensitivity of the prostate cancer cells by affecting their adhesive properties, although this remains to be determined.
Based on the uncharacteristic cytoplasmic nature of this particular protocadherin gene product (compared to the standard membrane bound-nature of most cadherin family proteins) as well as the apparent ability of protocadherin-PC to bind to b-catenin, we are considering the possibility that the mechanistic action of protocadherin-PC in inducing apoptosisresistance in the LNCaP cells might be related to some abnormal activation of b-catenin signaling (i.e. abnormal end activation of the wnt signaling pathway). Indeed, our preliminary study of b-catenin distribution and activity in the LNCaP cell variants shows that bcatenin is abnormally present in abundance in the cytoplasm and nucleus of apoptosis-resistant LNCaP variants but is restricted to the membrane fraction of the parental (apoptosis-sensitive) cells (data not shown here). More experimental work will be required to prove this hypothesis and that work is ongoing. But it does support a recent report that abnormal b-catenin activity and cellular localization is associated with prostate cancer development and progression (Cheshire et al., 2002) .
Another intriguing aspect of our results is the finding that protocadherin-PC is encoded on the human Ychromosome. There are many reports of cytogenetic abnormalities involving the Y-chromosome in human prostate cancer cells but the consistency of these reports is not clear since some studies report that the chromosome is consistently amplified while others describe loss of the entire, or portions, of Y (Takahashi et al., 1996; Brothman, 1997; Tricoli, 1999) . Recent reports show that Y-chromosome associated gene products are expressed in several prostate cancer cells (Lau and Zhang, 2000; Dasari et al., 2001) , including LNCaP. Perhaps, more relevant to our findings, was a recent demonstration that prolonged culture of LNCaP cells (up to 81 passages) resulted in a less androgensensitive cell with gains in the Y-chromosome (Karan et al., 2001) . The idea that a human-specific, Y-chromosomally-localized gene product has the ability to affect prostate cancer progression has dramatic implications for a malignant disease, prostate cancer, that is mainly restricted to humans and, of course, only found in males. Whereas protocadherin-PC expression may be only one of several molecular pathways through which prostate cancer cells might acquire their resistance to therapy, it certainly provides a potentially more intriguing pathway through which this might occur.
Materials and methods
Cultured cells
The parental LNCaP line (Horoszewicz et al., 1980) was obtained from the ATCC (Manassas, VA, USA) and was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin as previously described (Raffo et al., 1995) . These cells were passaged on a weekly basis using trypsin/EDTA. Apoptosisresistant variants of LNCaP cells were derived following a 24 h incubation of sub-confluent cultures in standard medium containing 10 nM phorbol 12-myristate 13-acetate (TPA) or in medium lacking serum (serum starvation) (see Figure 1) . We have previously reported that these conditions cause extensive apoptosis of parental LNCaP cells, eliminating up to 85% of the (subconfluent) parental cell culture (Raffo et al., 1995) . Following this, surviving cells were trypsinized and dispersed onto fresh plates where they were allowed to regrow again to subconfluence in normal medium. At this time, they were re-exposed to the same apoptotic-inducing agent for 24 h and surviving cells were re-passaged as before. On the fifth sequential exposure to the apoptotic agents, we noted that the agents no longer induced extensive loss of cells from the culture and we named the derivative lines LNCaP-TR (TPA-resistant) and LNCaP-SSR (serum starvationresistant). These cells were passaged twice prior to RNA extraction. The MTT assay was utilized to compare the sensitivity of the parental and variant cell lines to 10 nM TPA or to serum starvation (Raffo et al., 1995) . For other experiments, LNCaP cells were cultured for 5 or 10 days in a hormone-deficient medium supplemented with 10% charcoal-stripped FBS instead of FBS (Shen et al., 1997) .
Stable transfection of parental LNCaP cells using the protocadherin-PC cDNA cloned into the PC-3 neo vector was accomplished using lipofectin as previously described (Raffo et al., 1995) . Stably transfected cells were selected by incubation in a G418-containing medium as was described and were cloned using a cloning ring strategy.
RNA extraction and subtractive hybridization procedure
Total RNAs were extracted from parental LNCaP or from the LNCaP-TR and -SSR variants using guanidinium isothiocyanate extraction and cesium chloride centrifugation (Chirgwin et al., 1979) . Poly-(A)+ mRNA was selected by the total RNAs by chromatography on oligo-dT cellulose. Subtractive hybridization-PCR (comparing parental LNCaP cells to LNCaP-TR cells) (Diatchenko et al., 1996) was done with the use of the PCR-Selected Subtraction Kit as instructed by the manufacturer (Clonetech, Inc., Palo Alto, CA, USA). In this technique, Poly(A) + mRNAs from LNCaP and LNCaP-TR were first copied to cDNA using MMLV Reverse Transcriptase. The cDNAs were then digested with restriction endonuclease RsaI, to generate blunt ended DNA fragments. The restricted cDNA from the LNCaP-TR cells was designated the 'tester' cDNA and this cDNA was divided into two aliquots which were individually ligated to different adaptors. Each type of ligated tester cDNA was then heat denatured and hybridized to denatured 'driver' cDNA obtained from parental LNCaP cells. After hybridization, the two different forms of tester DNA were mixed and allowed to self-hybridize so that they formed hybrid double-stranded tester cDNAs with differing adapters at each end. This final population was subject to two sequential rounds of PCR using dual adapter sequences as the primer. The end result of this procedure was a reaction mixture containing PCR-amplified tester DNA sequences with different amplimers at each termini. These fragments were directly ligated into a pGEM cloning vector for transformation of competent E. coli and the recovery of viable bacterial colonies containing fragments of cDNA that are highly expressed in the tester (LNCaP-TR) cell line compared to the driver cell line (LNCaP parental).
Tumor xenografts in nude mice
Parental LNCaP cells (10 6 ) were mixed with 100 ml of Matrigel (Collaborative Biomedical Products/Becton Dickinson, Bedford, MA, USA) and were injected subcutaneously into the flanks of 12-week-old immunodeficient male (nude) mice as previously described (Raffo et al., 1995) . The mice were maintained under standard conditions with food and water available ad libitum under 12 h day/night cycles. When the tumors reached approximately 0.3 cm 3 in size, one group of mice (n=4) was sacrificed and their tumors were recovered and frozen for subsequent RNA extraction. Other groups o f mice bearing parental LNCaP tumors were castrated at this time via scrotal incision. These mice were maintained for 2 days or 4 weeks at which time groups (n=4) were sacrificed and the tumors were recovered and frozen. Tumor size was monitored by bi-weekly caliper measurements and evaluation of tumor volume as previously described (Raffo et al., 1995) .
For other experiments, 12-week-old male nude mice were castrated via scrotal incision and one week later, groups of these mice (n=8) were subcutaneously implanted with 10 6 parental LNCaP cells or with the LNCaP-TR or -SSR variants mixed with 100 ml of Matrigel. Tumor development and growth rates were monitored bi-weekly over an 8-week period.
Northern blotting and RNase protection assays
Total RNAs were extracted from the various cell lines or from pulverized frozen tumor xenografts using the RNazole method, as previously described (Zhang et al., 1994) . Aliquots of RNA (20 mgs) were electrophoresed on formaldehyde-agarose gels and were transferred to nylon filters by capillary blotting methods to produce a Northern blot. Blots were probed with the 32 P-labeled T6 tag sequence as previously described (Buttyan et al., 1988) . For RNase protection assays, total RNAs extracted from LNCaP tumors obtained from pre-castrated mice or from mice at 2 days or 4 weeks after castration were hybridized to a 32 P-labeled antisense riboprobe for T6 and were tested for protection of the 259-bp T6 sequence using the RPA II RNase Protection Assay Kit (Ambion, Inc., Austin, TX, USA) as previously described (Zhang et al., 1994) .
5' and 3' RACE procedures to amplify and clone protocadherin-PC cDNA
The SMART RACE cDNA Amplification kit (CLONTECH Laboratories, Inc. Palo Alto, CA, USA) was used to perform both 5' and 3'-rapid amplification of cDNA ends (RACE). The primers utilized were derived from the sequence of the T6 tag fragment that was derived by the subtractive hybridization-PCR procedure: GSP-1: 5'-GGA TAG CCA CAG TCA GAA ACG CTG TAG-3' (5' RACE) GSP-2: 5'-TTC AAG CCT GAC AGC CCT GAT TTG GCC-3' (3'-RACE). 1 mg of total RNA from the LNCaP-TR cell line was used for first-strand cDNA synthesis. For preparation of 5'-RACE-ready cDNA synthesis, 5'-cDNA Synthesis Primer (CDS) and SMART II oligo primer (Clontech Laboratories, Inc.) were mixed and denatured with the RNA. For preparation of 3'-RACE-ready cDNA synthesis, 3'-CDS primer was mixed and denatured with the RNA. First-strand cDNAs were then synthesized using MMLV reverse transcriptase as described by the manufacturer (Clonetech Laboratories, Inc.). Touchdown PCR was then performed to complete the 5' and 3' RACE amplifications. For 5' RACE, primers GSP-1 and UPM (universal primer mix, supplied by Clontech Laboratories, Inc.) were used, and for 3'-RACE, primer GSP-2 and UPM were used in the PCR amplification reactions. PCR was performed using the Perkin-Elmer GeneAmp System 9600 thermocycler under the following conditions: 948C for 5 s, 728C for 3 min, (five cycles); 948C for 5 s, 708C for 10 s, 728C for 3 min (five cycles); 948C for 5 s, 688C for 10 s, 728C for 3 min (25 cycles). The PCR products were cloned into pGEM-T Easy vector (Promega, Madison, WI, USA) and were sequenced using T7 and SP6 primers and internal sequencing primers, designed as needed.
The length of the complete cDNA was determined to be 4861 bp. After the 3' and 5' end sequence were established, two primers (5-END [5'-GTC CGG GAC GTA CAT TTT CGC GGT CCT G-3']; and 3-END [5'-CCT AGA AAG TTA CAT CTC ACT GCA GAT T-3']) were designed and used to obtain the intact cDNA coding sequence (positions: 688 -3763, 3076 bp) encompassing the translation start and stop codons of the longest open reading frame.
Computer analysis of the protocadherin-PC cDNA sequence Protocadherin-PC cDNA was compared to Genbank using the Fasta program (Pearson, 1996) as implemented in the GCG package. Prior to running Fasta, the query sequence was filtered with the Dust program to remove low complexity (highly repetitive sequences) that can cause false positives. The query sequence was found to be most similar to a portion of the human Y-chromosome genomic sequence, accession number ac010722, with an E value of 0. The sequence of protocadherin-PC cDNA also matches the cDNA with the accession number ac004383, a human Xchromosomal genomic sequence. Further regions of similarity were found between protocadherin PC cDNA and ac010722 by searching it with, as query sequence, those segments of protocadherin PC cDNA that were not included in the previous alignments. FASTA was also used for this purpose. Optimal alignments were achieved between segments of the two sequences using the Bestfit program, which is the GCG implementation of the Smith-Waterman algorithm (Smith and Waterman, 1981) . Comparison of the protocadherin-PC cDNA with the ac010722 genomic sequence yields a sequence identify of 100%.
Translation of the protocadherin cDNA sequence in all three forward frames was done with the GCG program Map. The first methionine of the longest open reading frame (ORF) was taken to be the translation start site. Translation of the sequence to form a peptide sequence was done with the GCG program Translate. Low complexity regions in the protein sequence were filtered with Seg (Wooton and Federhen, 1996) . The signal peptide and the signal peptide cleavage site of the longest open reading frame were identified with the Signal P web server (http://www.cbs.dtu.dk/services/ SignalP/) (Nielson et al., 1997) . The transmembrane region and the topology of the protein in the membrane were identified with the PHDhtm module of the PredictProtein web server (http://dodo.cpmc.columbia.edu/predictprotein/) (Rost et al., 1995 (Rost et al., , 1996 . The start of transcription was detected using the NNPP (neural Network Promoter Prediction) web server (http://www.hgc.lbl.gov/projects/ promoter.html) (Reese et al., 1996) .
Protocadherin-PC was analysed for cadherin repeats in three ways: (1) by comparing the sequence to the Prosite 15.0 profile datafase (Hoffman et al., 1999) with the Pfscan program (Bucher et al., 1996) on the Isrec server (http:// www.isrec.isb-sib. ch/software/PFSCAN_form.html); (2) by searching the Pfam 4.2 database (Sonnhammer et al., 1997) with the HMMER2 hidden Markov model (Eddy, 1998) package via the Washington University PFAM web server, (http://pfam.wustl.edu/hmmsearch.html); (3) by searching the Prosite 15.0 motif database with the GCG Motifs program. Method 1 recognized more cadherin domains than methods 2 or 3. Also the cadherin domains detected by method 1 were found to almost duplicate the overlap of those found by methods 2 and 3, therefore the result of method 1 is reported here.
Production of polyclonal anti-protocadherin-PC antibody; use in Western blotting and immunoprecipitation of protocadherin-PC A selected 15 amino acid peptide (E-E-T-K-A-D-D-V-D-S-D-G-N-R-V) from the predicted polypeptide sequence (amino acids 829 -843) of the longest open reading frame of protocadherin-PC cDNA sequence was synthesized (Genosys Biotechnologies, Inc., The Woodlands, TX, USA) and was then used for immunization of rabbits (at biweekly intervals) for a total of six immunizations. Blood was drawn and serum was separated and frozen in aliquots at 7208C (Genosys Biotechnologies, Inc.). For direct Western blot detection, the serum was diluted 1 : 1000 in PBS and was used to probe Western blots made from cytoplasmic extracts of LNCaP cell variants or tumor xenografts. Rabbit antibody binding to the Western blot was detected using a peroxidase-conjugated anti-rabbit IgG (Amersham, Inc., Arlington Heights, IL, USA) and the chemiluminescent detection reagents present in the ECL Western Blotting Analysis System (Amersham, Inc., Arlington Heights, IL, USA) as previously described (Raffo et al., 1995) . Protocadherin PC was directly immunoprecipitated from cytoplasmic extracts of various cultured LNCaP cell derivatives by incubation of extracts containing 200 mg of protein with an 10 ml aliquot of antiserum followed by immunoprecipitation using Protein-G Sepharose beads (Sigma Chemical Co., Inc., St. Louis, MO, USA). Immunoprecipitates were eluted from the beads in SDS and were electrophoresed on 8% SDS-polyacrylamide gels prior to transfer to a nitrocellulose filter to produce a Western blot.
Protein extraction and Western blotting
Fractionated protein extracts were made from the parental LNCaP, LNCaP-SSR and LNCaP-TR lines. After washing the cells in PBS, they were resuspended in 5 vol of buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgC1 2 and 0.5 mM DTT) and incubated for 10 min on ice. The cells were lysed by homogenization with a Polytron tissue homogenizer (Brinkmann Instruments, Westbury, NY, USA). The homogenate was centrifuged for 10 min at 3500 r.p.m. and the supernatant was designated the cytoplasmic protein fraction. The pellet was resuspended in 0.11 vol of buffer B (0.15 M HEPES, pH 7.9, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 0.015 mg/ml aprotinin) and was centrifuged at 100 000 g for 60 min. The supernatant of this extract (containing the membrane protein fraction) was dialyzed 5 to 8 h against buffer D (20 mM HEPES, 20% (v/v) glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 0.5 mM DTT).
The nuclear protein fraction was extracted as described by Dignam et al. (1983) . After washing cells in PBS, they were suspended in five packed cell pellet volumes of buffer A and allowed to stand 10 min. The cells were collected by centrifugation and lysed in 2 vol buffer A by 10 strokes of a Kontes all glass Dounce homogenizer. The homogenate was centrifuged for 10 min at 2000 r.p.m. The pellet was suspended in buffer A (1 ml) and was centrifuged at 25 000 g for 20 min. The pellets (crude nuclei) were resuspended in buffer C (3 ml for 10 9 cells, 20 mM HEPES (pH 7.9), 25% (v/ v) glycerol, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT) and were homogenized with the Polytron tissue homogenizer. The suspension was stirred gently for 30 min and centrifuged for 30 min at 25 000 g. The resulting clear supernatant was dialyzed against 50 vol of buffer D for 5 h. The dialysate was centrifuged at 25 000 g for 20 min and the supernatant was considered to be the nuclear protein fraction. For Western blotting, 50 mg aliquots of each protein fraction were co-electrophoresed on a 8% acrylamide SDS gel. After electrotransfer to nitrocellulose membranes, Western blots were probed with the polyclonal rabbit antibody generated as described above. Other Western blots were generated using proteins extracted directly from the variant LNCaP cell lines using RIPA buffer as was previously described (Raffo et al., 1995) . These blots were probed with mouse monoclonal antibodies against human androgen receptor (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), human prostate specific antigen (Dako, Inc., Carpenteria, CA, USA), bcl-2 (Santa Cruz Biotechnology, Inc.), bcl-X L (Santa Cruz Biotechnology, Inc.), p53 (Dako, Inc.) or erb-B2/neu (Dako, Inc.) using an Amersham ECL chemiluminescent detection system (Amersham Inc., Arlington, IL, USA).
